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choice instrument to elicit women’s tradeoff preferences for
various treatment attributes, including both beneﬁts and risks 
for therapies to relieve vasomotor symptoms. The survey was
administered to 500 US women between the ages of 46 and 60,
randomly sampled from a large internet consumer panel. Two
survey versions were administered to split samples. The versions
were identical except that risk descriptions incorporated relative
risks in one version and absolute risks in the other version.
Ordered-probit importance weights for various health states and
risks were estimated from the resulting tradeoff data. RESULTS:
We found that the risk description did not affect ordered-probit
estimates of respondents’ preferences for risk of fracture and
heart attack, but did affect preferences for the risk of breast
cancer. Subjects who received the relative-risk versions indicated
that a decrease in risk of breast cancer from 3.9% to 2.3% was
64% more important than subjects who received the absolute-
risk version. Conversely, subjects who received the absolute-risk
version were more concerned about relieving vasomotor symp-
toms. Relieving the severity of hot ﬂashes was 44% more impor-
tant, reducing the frequency of hot ﬂashes was 40% more
important, and reducing the frequency of night sweats was 50%
more important for subjects who received the absolute-risk
version than for subjects who received the relative risk version.
CONCLUSION: Although health professionals presumably
interpret clinical relative-risk results in the context of the base
prevalence of a condition, laypersons often do not have access
to base-rate information. Our results suggest that more careful
characterization of adverse-event risks is important in helping
women make fully informed choices among alternative treat-
ments for vasomotor symptoms.
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OBJECTIVES: EQ-5D is one of the most widely used index mea-
sures of health-related quality of life. Ten years have passed since
the ﬁrst UK national survey that established preference weights
for EQ-5D health states. That protocol elicited values for 45 of
the 245 possible EQ-5D health states. Values for the remaining
health states were interpolated from estimation models based on
the values for directly observed states. The process of model con-
struction and testing was onerous and labour intensive. Esti-
mated values remained largely untested as replication studies are
virtually non-existent. This paper reports on an alternative
approach in which values for ALL health states are elicited.
METHODS: The standard questionnaire used to value EQ-5D
health states records VAS ratings on a 0–100 scale, for 16 health
states presented as two groups of eight on consecutive pages. 
The logically best and worst health states are repeated on each
page. A value for dead is also elicited in each questionnaire. 
For this study, 21 versions of the questionnaire were designed,
each presenting 14 different states. Questionnaires were mailed
to 1100 individuals selected randomly from the electoral regis-
ters of England and Wales. RESULTS: A response rate of 62%
was achieved (n = 685). Mean VAS scores from this survey 
were similar to those elicited ten years earlier although the 
value for dead was 45% higher than its predecessor. A smooth,
well-behaved set of values for all 245 states was derived using
OLS regression (r2 = 0.974, p < 0.001). Transformed to a 0–1
scale, values were systematically higher than the corresponding
TTO weights used as standard in NICE appraisals reporting EQ-
5D. Only 12 states demonstrate negative values. CONCLU-
SIONS: Traditional interview-based procedures are costly. This
study demonstrates the feasibility of postal survey methods and
simultaneously poses a dilemma for end-users. Are contempo-
rary VAS–based values preferable to decade old TTO-based
values?
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OBJECTIVES: The FDA currently requires patient interviews in
the process of developing a new PRO measure. In the past, many
questionnaires were developed based solely on clinician exper-
tise and patient involvement in the creation of items was non-
existent. In order to ensure existing questionnaires are accepted
by the FDA, it is necessary to conﬁrm the content validity of
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questionnaires that were not based on patient interviews. The 25
and 18 item RMDQ is a measure of pain and function widely
used in low back pain (LBP) trials that was based solely on clin-
ician involvement. METHODS: Two US focus groups (n = 15)
and one UK focus group (n = 7) were asked to complete the
problem elicitation technique (PET) alongside the RMDQ to
determine the relevance of items. The PET measures the impor-
tance of concepts based on a series of questions rating the impor-
tance of each item on a ﬁve-point likert response continuum. To
ensure the RMDQ was not missing any relevant items partici-
pants were asked several open-ended questions. RESULTS: Par-
ticipants conﬁrmed the content validity of the RMDQ by
identifying four areas of importance: pain/discomfort, activities
of daily living, sleep problems and emotional impact. Based on
the PET, all RMDQ items were rated as moderately to extremely
important (item score range of 3.57–4.36 on a one—ﬁve scale).
Items rated least important were the same items removed in the
18 item version. In the open ended questions, sleep disturbances
was consistently mentioned as a primary area of concern. CON-
CLUSIONS: The PET augmented by open-ended questions is a
valid method for conﬁrming the content validity of question-
naires that did not include patient involvement in their develop-
ment. These ﬁndings support the continued use of the RMDQ
in LBP trials; however, consideration should be given to includ-
ing additional sleep questions or measuring this concept 
separately.
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OBJECTIVES: To determine whether Home Automated Telem-
anagement (HAT) affects disease-speciﬁc Quality of Life (QOL)
in adult asthma patients. METHODS: Fifty adult patients with
mild persistent to severe asthma were randomly assigned to an
intervention or control group and were followed for 12 months.
The patients in the control group received regular care. The
patients in the intervention group used HAT to monitor and
manage their condition. The HAT system assisted clinicians in
setting up individualized action plans and helped asthma patients
in following their action plans at home using peak ﬂow meter
and a laptop connected with a hospital. RESULTS: Both inter-
vention and control group patients had similar baseline demo-
graphic characteristics with regard to their asthma severity,
action plan use, computer skills and the quality of life. After 12-
month follow-up the mean total QOL score in the intervention
and the control group was 20.2 ± 0.9 and 16.9 ± 1.3 respec-
tively. The difference was signiﬁcant (p < 0.0001) at the alpha
level of 0.05. Analysis of the symptoms domain of the asthma
quality of life showed improved score 5.3 ± 0.4 in the interven-
tion group compared to the control group 4.4 ± 0.6 (p < 0.05).
The activities domain of the QOL showed an improvement in
the activities in the intervention group 5.1 ± 0.2 compared to the
control group 3.7 ± 0.3 (p < 0.05). There was a statistically sig-
niﬁcant difference (p < 0.05) in the emotions domain of the
QOL: the mean score in the intervention group was 4.8 ± 0.2
whereas the mean score in the control group was 4.4 ± 0.4. The
environment domain in the intervention group was 5.1 ± 0.3
compared to 4.4 ± 0.5 in the control group (p < 0.005). CON-
CLUSION: Disease-speciﬁc quality of life in asthma patients is
positively affected by Home Telemanagement.
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OBJECTIVES: To assess health-related quality-of-life (HRQOL)
for patients with chronic obstructive pulmonary disease (COPD).
METHODS: In Spring 2004, 700 patients cared for by pulmo-
nologists or general practitioners at 12 sites across the US com-
pleted a 90-item survey that included the SF-12v2 and
pre-/post-bronchodilator spirometry. COPD was deﬁned as post-
bronchodilator Forced Expiratory Volume in one second/Forced
Vital Capacity (FEV1/FVC) <70%. Descriptive statistics for SF-
12v2 measures were calculated for mild (FEV1 >80% predicted)
and moderate/severe (FEV1 <80% predicted) COPD. Disease
burden was estimated by adjusting general population norma-
tive data from the 1998 National Survey of Functional Health
Status (NSFHS) to age and sex characteristics of the COPD
sample. Multivariate and univariate analyses of variance
(MANOVA, ANOVA) F-statistics were used to test for differ-
ences between patients’ HRQOL and adjusted norms. RESULTS:
Based on spirometry, 36% (N = 249) of patients had COPD
(20% mild, 80% moderate/severe). Patients with COPD were
less likely to describe their health as very good or excellent
(20.5% vs. 36.8%, p < 0.001), and more likely to describe their
health as fair or poor (33.3% vs. 23.4%, p < 0.005) compared
to those without COPD. MANOVA revealed a signiﬁcant dif-
ference between the full proﬁle of SF-12v2 scales for COPD
patients and the US general population (p < 0.001). Adjusted
norm comparisons revealed that patients with mild COPD had
signiﬁcantly lower (mean, SD) Role Physical (41.9, 11.1; p <
0.02) and Physical Component Summary (PCS) (41.0, 12.0; p <
0.02) scores. Moderate/severe COPD patients had large, statisti-
cally signiﬁcant decrements across all SF-12v2 measures. Differ-
ences from normative values were most notable for Physical
Functioning (38.2, 12.8; p < 0.001), PCS (38.9, 11.7; p < 0.001),
Role Physical (39.7, 11.9; p < 0.001), General Health (40.8,
11.2; p < 0.001), and Role Emotional (43.0, 13.0; p < 0.001).
CONCLUSION: Compared to the US general population,
COPD has a signiﬁcant impact on a patient’s HRQOL, notable
with mild disease and pronounced at higher severity levels.
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OBJECTIVES: To explore the cost-effectiveness of ﬂuticasone
propionate (FP) for the treatment of chronic obstructive pul-
monary disease (COPD), we estimated costs and quality adjusted
life years (QALYs) over three-years, based on an economic
appraisal of a previously reported clinical trial (ISOLDE).
METHODS: Results from the initial analyses of the trial data
showed signiﬁcant improvements with FP in reducing the rate of
exacerbations from COPD, in slowing the rate of decline in
health status and a trend towards improved survival. A recently
